HeraMED adds telehealth services to Herabeat in Germany
  • Medical technology company HeraMED will partner with German midwife service provider, Kinderheldin, to add a telehealth service to its portfolio
  • The company's HeraBEAT device allows expecting mothers to monitor their baby's heart beat using an ultrasonic monitor
  • The agreement will see the release of HeraBEAT plus, that will provide online midwife support to mothers using the device
  • Existing partner Duttenhofer will also be involved in the two-year agreement
  • Shares are down 4.08 per cent and trading for 23.5 cents each

Medical technology company HeraMED will partner with midwife service provider Kinderheldin to launch a telehealth service.

Kinderheldin, a German company, already has an online platform where expecting parents can talk to midwives.

The new partnership will see HeraMED's foetal heartbeat monitor, HeraBEAT, connected to Kenderheldin's online midwife service. The telehealth feature will be incorporated into a new device, the HeraBEAT Plus and launched in Germany.

Kinderheldin's midwives will be able to access the heartbeat information via the platform to provide more informed and immediate advice.

Initially, the telehealth feature will be complimentary and then be operated as a subscription service.

In addition to the two-year agreement with Kinderheldin, HeraMED has tabled plans for the two companies to commence discussion regarding the product with both healthcare providers and insurance companies in Germany. Kinderheldin is well connected with over 50 insurance company partnerships and 5 major hospital partnerships.

Existing partner Duttenhofer Group will also be part of the HearBEAT Plus collaboration. In August this year, HeraMED announced an agreement with Duttenhofer to distribute HeraBEAT in Germany, Austria and Switzerland.

HeraMED shares are down 4.08 per cent and trading for 23.5 cents each at 2:20 pm.


HMD by the numbers
More From The Market Herald
HeraMED (ASX:HMD) - CEO & Co Founder, David Groberman - The Market Herald

" HeraMED (ASX:HMD) announces share purchase plan results

Pregnancy technology company HeraMED (HMD) has received $233,000 in applications via its recent share purchase plan.
MGC Pharma (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald

" MGC Pharmaceuticals (ASX:MXC) granted Cannabis Research Cultivation Permit

MGC Pharmaceuticals (MXC) has been granted a Cannabis Research Cultivation Permit (CRCP) from the Australian Office of Drug Control (ODC).
Alcidion Group (ASX:ALC) - Gropu Managing Director, Kate Quirke - The Market Herald

" Alcidion Group (ASX:ALC) signs two contracts with Murrumbidgee Local Health District

Alcidion Group (ALC) has signed two contracts with Murrumbidgee Local Health District (LHD) for continued use of Alcidion’s Miya Precision platform and Miya
Imugene (ASX:IMU) - CEO & Managing Director, Leslie Chong - The Market Herald

" Imugene (ASX:IMU) receives ethics approval for PD1-Vaxx trial

Biotech company Imugene (IMU) has received Human Research Ethics Committee (HREC) approval to begin a phase one clinical trial of PD1-Vaxx in Australia.